Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Alongside the amended certificate, Metsera, Inc. also updated its bylaws.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) ("Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company ...

This time, the company plans to sell $1 billion worth of stock and hit an $11.5 billion valuation in its planned IPO. That’s how the math works out for a proposed offering it announced Tuesday ...

Other hedge funds previously invested in Maze but not listed in the IPO filing as 5 percent owners: Casdin Capital, Deep Track Capital, and Woodline Partners. On Monday, Sionna Therapeutics said ...

Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that ...

Dr Agarwal’s Healthcare IPO Listing: The equity shares of Dr Agarwal’s Health Care Ltd are set to be listed on stock exchanges tomorrow, February 4, after a lukewarm response to its initial ...

Notably, Metsera (MTSR, NC), an emerging player in the obesity market, saw its stock soar by 47% on its first trading day. Merger and acquisition (M&A) activities in the biotech space were few but ...

Sionna is working out its IPO plans days after obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics both listed on the Nasdaq with offerings of $275 million and $140 million ...